Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Drug resistance, a significant challenge in cancer treatment, necessitates the development of novel therapeutic strategies.
• Cancer cells develop various defense mechanisms leading to multidrug resistance (MDR), a primary cause of treatment failure.
• Chalcones, naturally occurring compounds, exhibit diverse biological activities and interact with multiple targets within cancer cells.

Purpose of the Study:

• To review recent advancements in chalcone derivatives as potential treatments for drug-resistant cancers.
• To consolidate research published between 2010 and 2020 on chalcone derivatives targeting resistant cancer types.
• To provide insights for the rational design of more potent anticancer agents derived from chalcones.

Main Methods:

• Literature review focusing on scientific articles published from 2010 to 2020.
• Analysis of studies investigating the anticancer activity of chalcone derivatives against various cancer models, including drug-resistant and multidrug-resistant types.
• Synthesis and evaluation of structure-activity relationships (SAR) of chalcone derivatives.

Main Results:

• Chalcone derivatives demonstrate significant cytotoxic effects against a broad spectrum of cancers, including those exhibiting resistance.
• Specific structural modifications of chalcones enhance their potency and ability to overcome multidrug resistance mechanisms.
• Several chalcone derivatives have shown promising preclinical results, highlighting their therapeutic potential.

Conclusions:

• Chalcone derivatives represent a promising class of compounds for overcoming cancer drug resistance.
• Further research and rational drug design based on chalcone scaffolds can lead to the development of next-generation anticancer therapies.
• Targeting drug-resistant cancers with novel chalcone-based agents is a viable strategy in oncology.